Group 1 - The core viewpoint of the news is that Li Cheng Asset recently conducted a research on a listed company, focusing on the operations and competitiveness of the Kasima platform, which is a procurement platform for scientific research products [1] - The Kasima platform operates independently from the Chinese Academy of Sciences, with a wide business coverage, including 247,000 registered members, over 1,800 research institutions, and 10,218 suppliers, achieving an annual transaction volume of nearly 4 billion yuan [1] - Revenue sources for the Kasima platform include store fees, bridge fees, value-added service fees, and advertising fees, with 2023 profits being high due to non-recurring income, while a decline in 2024 profits is not attributed to core business operations [1] Group 2 - Li Cheng Asset is one of the earliest established private equity management companies in China, with a focus on growth stock investment and a complete investment management knowledge system [2] - The company has a team of 50 employees, with nearly 30 being professional research and investment personnel, managing a maximum scale of over 10 billion yuan, and specializing in secondary stock long strategies and PIPE strategies in the fields of pharmaceuticals, advanced manufacturing, and consumer goods [2] - Li Cheng Asset has received multiple awards, including three private equity Golden Bull Awards, indicating strong long-term performance [2]